1
|
Diaz KA, Amaya SL, García-Perdomo HA. Perspectives on prostate cancer: advances and pending challenges for a multidisciplinary oncological approach in South America. Int Urol Nephrol 2024; 56:1-7. [PMID: 37698709 PMCID: PMC10776746 DOI: 10.1007/s11255-023-03753-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2023] [Accepted: 08/14/2023] [Indexed: 09/13/2023]
Abstract
Prostate cancer is one of the tumors with the highest incidence and mortality among men worldwide, and this situation is no different in South America. However, epidemiological data are highly variable for each country and even more so than in North America. These data may be influenced by the very low rate of early detection of disease, availability of diagnostic methods, proper data collection, and limited access to specialized multidisciplinary treatment. For many South American countries, academic referral centers can only offer state-of-the-art diagnostics and multidisciplinary cancer treatment for patients who live in or can travel to large cities, so most patients are cared for by non-expert urologists with limited resources, which can have a negative impact on their prognosis and worsen oncologic outcomes. We aimed to show the clinical management of prostate cancer patients, the current advances in management, limitations present in South America, and how a multidisciplinary approach in referral cancer centers conformed of specialized urologists, medical oncologists, and mental health professionals can maximize patient outcomes.
Collapse
Affiliation(s)
- Kevin A Diaz
- UROGIV Research Group, Department of Surgery, School of Medicine, Universidad del Valle, Cll 4B #36-00, Cali, Colombia
| | - Sandra Liliana Amaya
- UROGIV Research Group, Department of Surgery, School of Medicine, Universidad del Valle, Cll 4B #36-00, Cali, Colombia
| | - Herney Andrés García-Perdomo
- UROGIV Research Group, Department of Surgery, School of Medicine, Universidad del Valle, Cll 4B #36-00, Cali, Colombia.
- Division of Urology/Urooncology, Department of Surgery, School of Medicine, Universidad del Valle, Cali, Colombia.
| |
Collapse
|
2
|
Simbaña-Rivera K, Torres-Roman JS, Challapa-Mamani MR, Guerrero J, De la Cruz-Ku G, Ybaseta-Medina J, Martinez-Herrera JF. Regional disparities of prostate cancer mortality in Ecuador: an examination of trends and correlates from 2004 to 2019. BMC Public Health 2023; 23:992. [PMID: 37248460 DOI: 10.1186/s12889-023-15941-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/20/2022] [Accepted: 05/19/2023] [Indexed: 05/31/2023] Open
Abstract
BACKGROUND Prostate cancer is the leading cause of cancer death in Ecuadorian men. However, there is a lack of information regarding the evolution of prostate cancer mortality rates in Ecuador and its regions in the last few decades. OBJECTIVE The aim of this study was to report prostate cancer mortality rates in Ecuador and its geographical areas and observe the evolution of these rates between 2004 and 2019. METHODS An observational ecological study was conducted, analysing data for prostate cancer deaths from 2004 to 2019 in Ecuador. Age standardized mortality rates (ASMR) were calculated per 100,000 men using the world standard population with the direct method proposed by SEGI. Joinpoint regression analysis was performed to examine mortality trends. We used a Cluster Map to explore relationships among regions between 2015 and 2019. RESULTS Ecuador reported 13,419 deaths by prostate cancer between 2004 and 2019, with the Coastal region accounting for 49.8% of the total deaths. The mean age at death was 79 years (± 10 years), 91.7% were elderly (more than 65 years old) and had primary education (53%). Deaths by prostate cancer were more frequently reported among mestizos (81.4%). There were no significant variations in these percentages in Ecuador and its regions during the study period. Carchi province had the highest mortality rate in 2005 and 2019 (> 13 deaths per 100,000). Heterogeneity in the evolution of mortality rates was reported among the provinces of Ecuador. Azuay decreased in the first few years, and then increased from 2010 to 2019, whereas Guayas and Pichincha decreased throughout the whole period. CONCLUSION Although prostate cancer mortality rates in Ecuador have remained stable over the past few decades, there are significant disparities among the different regions. These findings suggest the need for the development of national and provincial registration measures, integrated healthcare actions, and targeted interventions to reduce the burden of prostate cancer in the Ecuadorian population.
Collapse
Affiliation(s)
- Katherine Simbaña-Rivera
- Centro de Investigación para la Salud en América Latina (CISeAL), Facultad de Medicina, Pontificia Universidad Católica del Ecuador (PUCE), Quito, Ecuador
- Toxicology Unit, Research Institute of Biomedical and Health Sciences (IUIBS), Universidad de Las Palmas de Gran Canaria (ULPGC), Paseo Blas Cabrera s/n, Las Palmas de Gran Canaria, 35016, Spain
- Latin American Network for Cancer Research (LAN-CANCER), Lima, Peru
| | - J Smith Torres-Roman
- Escuela Profesional de Medicina Humana, Universidad Privada San Juan Bautista, Ica, Filial Chincha, Perú.
| | - Mabel R Challapa-Mamani
- Latin American Network for Cancer Research (LAN-CANCER), Lima, Peru
- Sociedad Cientifica de Estudiantes de Medicina de la Universidad César Vallejo, Trujillo, Perú
| | - Jhon Guerrero
- Latin American Network for Cancer Research (LAN-CANCER), Lima, Peru
- Scientific Association of Medical Students, Universidad Central del Ecuador, Quito, Ecuador
| | | | - Jorge Ybaseta-Medina
- Latin American Network for Cancer Research (LAN-CANCER), Lima, Peru
- Universidad Nacional San Luis Gonzaga de Ica, Ica, Peru
| | - José F Martinez-Herrera
- Latin American Network for Cancer Research (LAN-CANCER), Lima, Peru
- Cancer Center, Medical Center American British Cowdray, Mexico City, Mexico
| |
Collapse
|
3
|
Torres-Roman JS, Quispe-Vicuña C, Arce-Huamani MA, Dávila-Hernandez CA, Valcarcel B, Martinez-Herrera JF. Prostate Cancer Mortality in Peru: An Update from 2003 to 2017. Asian Pac J Cancer Prev 2022; 23:3623-3628. [PMID: 36444573 PMCID: PMC9930958 DOI: 10.31557/apjcp.2022.23.11.3623] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/12/2021] [Indexed: 11/30/2022] Open
Abstract
OBJECTIVE We estimated the mortality trends for prostate cancer in Peru and its geographical areas between 2003 and 2017. MATERIAL AND METHODS We obtained recorded prostate cancer deaths from the Peruvian Ministry of Health Database between 2003 and 2017. Age-adjusted mortality rates per 100,000 men-year were computed with the direct method using the world standard SEGI population. We estimated the annual percent change (APC) using the Joinpoint regression program. RESULTS A total of 38,617 prostate cancer deaths were reported between 2003 and 2017, with a mortality rate ranging from 18.21 to 19.94 deaths per 100,000 men-year. Since 2006, Peru has experienced a decrease of 2.2 deaths per year, whereas the mortality rate in the coastal region has declined by 2.9% per year. The highlands and rainforest regions showed stable trends throughout the entire study period. According to provinces, only Moquegua had a significant decrease (APC: -6.0, 95%CI: -11.4, -0.2, p<0.05) from 2003 to 2017. CONCLUSIONS Although mortality rates are decreasing, there is a high mortality burden by prostate cancer in Peru and by geographical regions, being mostly concentrated in the coastal region. The rainforest provinces deserve the most attention. Our findings suggest wide health care disparities among the different regions of Peru that need greater public health attention to reduce the burden of mortality by prostate cancer.
Collapse
Affiliation(s)
- J Smith Torres-Roman
- Cancer Research Networking, Scientific University of the South, Lima, Peru. ,Latin American Network for Cancer Research (LAN–CANCER), Lima, Peru. ,Professional School of Human Medicine, San Juan Bautista Private University, Chincha Branch, Ica, Peru. ,For Correspondence:
| | | | - Miguel A Arce-Huamani
- Cancer Research Networking, Scientific University of the South, Lima, Peru. ,Latin American Network for Cancer Research (LAN–CANCER), Lima, Peru.
| | - Carlos A Dávila-Hernandez
- Latin American Network for Cancer Research (LAN–CANCER), Lima, Peru. ,Professional School of Human Medicine, San Juan Bautista Private University, Chincha Branch, Ica, Peru.
| | - Bryan Valcarcel
- Latin American Network for Cancer Research (LAN–CANCER), Lima, Peru.
| | - José Fabián Martinez-Herrera
- Latin American Network for Cancer Research (LAN–CANCER), Lima, Peru. ,Cancer Center, Medical Center American British Cowdray, Mexico City, Mexico.
| |
Collapse
|
4
|
Beltran-Ontiveros SA, Fernandez-Galindo MA, Moreno-Ortiz JM, Contreras-Gutierrez JA, Madueña-Molina J, Arambula-Meraz E, Leal-Leon E, Becerril-Camacho DM, Picos-Cardenas VJ, Angulo-Rojo C, Velazquez DZ, Jimenez-Trejo F, Gallardo-Vera F, Diaz D. Incidence, Mortality, and Trends of Prostate Cancer in Mexico from 2000 to 2019: Results from the Global Burden of Disease Study 2019. Cancers (Basel) 2022; 14:cancers14133184. [PMID: 35804962 PMCID: PMC9265044 DOI: 10.3390/cancers14133184] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2022] [Revised: 06/05/2022] [Accepted: 06/28/2022] [Indexed: 02/05/2023] Open
Abstract
Simple Summary Worldwide, prostate cancer (PC) causes high morbidity and mortality. Thus, developing effective strategies for the prevention, diagnosis, and control of this disease is fundamental to providing updated and reliable estimations of the PC burden both nationally and subnationally. Herein, we analyzed data from the Global Burden of Disease study to estimate PC incidence and mortality, and their trends in Mexico at the national and subnational levels from 2000 to 2019. Our results show that PC was the top ranked cause of death among malign neoplasms in males from Mexico during 2019. Males from 70 to 79 years of age were the most affected by PC, and there was an increasing trend in the burden of this cancer. There was substantial subnational heterogeneity that suggested differential geographical patterns of change. These results provide both comprehensive and comparable estimates to assist the effort to reduce health loss due to PC. Abstract In 2019, the Global Burden of Disease (GBD) estimated that prostate cancer (PC) was the 16th most common cause of death globally in males. In Mexico, PC epidemiology has been studied by a number of metrics and over various periods, although without including the most up-to-date estimates. Herein, we describe and compare the burdens and trends of PC in Mexico and its 32 states from 2000 to 2019. For this study, we extracted online available data from the GBD 2019 to estimate the crude and age-standardized rates (ASR per 100,000 people) of the incidence and mortality of PC. In Mexico, PC caused 27.1 thousand (95% uncertainty intervals, 20.6–36.0 thousand) incident cases and 9.2 thousand (7.7–12.7 thousand) deaths in males of all ages in 2019. Among the states, Sinaloa had the greatest ASR of incidence, and Guerrero had the highest mortality. The burden of PC showed an increasing trend, although the magnitude of change differed between metrics and locations. We found both an increasing national trend and subnational variation in the burden of PC. Our results confirm the need for updated and timely estimates to design effective diagnostic and treatment campaigns in locations where the burden of PC is the highest.
Collapse
Affiliation(s)
- Saul A. Beltran-Ontiveros
- Posgrado en Ciencias Biomédicas, Facultad de Ciencias Químico Biológicas, Universidad Autónoma de Sinaloa, Culiacán Rosales 80010, Sinaloa, Mexico;
| | - Martha A. Fernandez-Galindo
- Doctorado en Genética Humana, Departamento de Biología Molecular y Genómica, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico
- Instituto de Genética Humana “Dr. Enrique Corona Rivera”, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico;
- Correspondence: (M.A.F.-G.); (D.D.)
| | - Jose M. Moreno-Ortiz
- Instituto de Genética Humana “Dr. Enrique Corona Rivera”, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico;
| | - Jose A. Contreras-Gutierrez
- Centro de Investigación y Docencia en Ciencias de la Salud, Universidad Autónoma de Sinaloa, Culiacán Rosales 80030, Sinaloa, Mexico;
| | - Jesus Madueña-Molina
- Facultad de Medicina, Universidad Autónoma de Sinaloa, Culiacán Rosales 80246, Sinaloa, Mexico; (J.M.-M.); (V.J.P.-C.); (C.A.-R.)
| | - Eliakym Arambula-Meraz
- Laboratorio de Genética y Biología Molecular, Facultad de Ciencias Químico Biológicas, Universidad Autónoma de Sinaloa, Culiacán Rosales 80010, Sinaloa, Mexico; (E.A.-M.); (E.L.-L.)
| | - Emir Leal-Leon
- Laboratorio de Genética y Biología Molecular, Facultad de Ciencias Químico Biológicas, Universidad Autónoma de Sinaloa, Culiacán Rosales 80010, Sinaloa, Mexico; (E.A.-M.); (E.L.-L.)
| | - Delia M. Becerril-Camacho
- Laboratorio de Biomedicina, Universidad Autónoma de Occidente, Unidad Regional Culiacán, Culiacán Rosales 80020, Sinaloa, Mexico;
| | - Veronica J. Picos-Cardenas
- Facultad de Medicina, Universidad Autónoma de Sinaloa, Culiacán Rosales 80246, Sinaloa, Mexico; (J.M.-M.); (V.J.P.-C.); (C.A.-R.)
| | - Carla Angulo-Rojo
- Facultad de Medicina, Universidad Autónoma de Sinaloa, Culiacán Rosales 80246, Sinaloa, Mexico; (J.M.-M.); (V.J.P.-C.); (C.A.-R.)
| | - Diana Z. Velazquez
- Departamento de Biomedicina Molecular, Centro de Investigación y de Estudios Avanzados, Gustavo A. Madero 07360, Ciudad de México, Mexico;
| | - Francisco Jimenez-Trejo
- Laboratorio de Morfología Celular y Tisular, Instituto Nacional de Pediatría, Coyoacán 04530, Ciudad de México, Mexico;
| | - Francisco Gallardo-Vera
- Laboratorio de Biología Molecular y Bioseguridad Nivel III, Centro Médico Naval, Coyoacán 04470, Ciudad de México, Mexico;
| | - Daniel Diaz
- Centro de Ciencias de la Complejidad (C3), Universidad Nacional Autónoma de México, Coyoacán 04510, Ciudad de México, Mexico
- Correspondence: (M.A.F.-G.); (D.D.)
| |
Collapse
|
5
|
Abstract
We estimated cancer mortality statistics for the current year in seven major Latin American countries, with a focus on colorectal cancer. We retrieved official death certification data and population figures from the World Health Organization and the Pan American Health Organization databases. We analysed mortality from all neoplasms combined and for selected cancer sites. We estimated numbers of deaths and age-standardized mortality rates for the year 2021 using a logarithmic Poisson count data joinpoint model. Total cancer mortality is predicted to decline in all countries considered for both sexes, with the exception of Argentinian women. The lowest total mortality rates were predicted in Mexico (65.4/100 000 men and 62.3 in women), the highest ones were in Cuba (133.3/100 000 men and 91.0 in women). Stomach cancer rates have been decreasing since 1970 in all countries; colorectal cancer started to decline over recent calendar periods. Rates for this cancer were unfavourable in the youngest age group. Lung cancer trends declined in males and remained comparatively low in all countries except Cuba. In Cuba, lung cancer rates in women overtook those for breast. Mortality from cancers of the breast, (cervix) uterus, ovary, prostate and bladder, as well as leukemia mostly showed favourable trends. A marked variability in rates across Latin American countries persists, and rates were relatively high for stomach, uterus, prostate and lung cancers, as compared to Europe and North America, suggesting the need to improve preventive strategies. Colorectal cancer mortality was relatively low in Latin America, except in Argentina, and short-term predictions remain moderately favourable.
Collapse
|
6
|
Liu K, Ma Y, Yang Y, Lu J, Zhao J, Du S, Zhang X, Liu C, Del Giudice F, Shiota M, Hatakeyama S, Zhang X, Kang J. Evaluation of the reporting quality of clinical practice guidelines on prostate cancer using the RIGHT checklist. ANNALS OF TRANSLATIONAL MEDICINE 2021; 9:1173. [PMID: 34430614 PMCID: PMC8350620 DOI: 10.21037/atm-21-2956] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/16/2021] [Accepted: 06/24/2021] [Indexed: 11/29/2022]
Abstract
Background The International Reporting Items for Practice Guidelines in Healthcare (RIGHT) statement is a set of recommendations for reporting in clinical practice guidelines (CPGs). We aimed to use RIGHT to evaluate the reporting quality of CPGs on prostate cancer. Methods We systematically searched literature databases and websites from January 1, 2018 to December 1, 2020 to identify CPGs on prostate cancer. Two investigators reviewed the identified articles and assessed the reporting quality independently by using the RIGHT checklist. We reported the proportions of guidelines that complied with each of the 35 RIGHT checklist item and the mean reporting compliance percentages for each of the seven domains of RIGHT. Results A total of 38 CPGs were included. The mean overall reporting rate over the included CPGs was 51.6%. Eighteen items were reported by more than half of the guidelines four items (1a 3, 7a and 13a) were reported by all guidelines. Items 7b (10.5%), 13b (10.5%), 14c (13.2%), and 18b (7.9%) had the lowest reporting proportions. The mean reporting rates in each RIGHT domain were 74.6% for “Basic Information”, 26.3% for “Review and quality assurance”, 59.9% for “Background”, 43.7% for “Evidence”, 43.2% for “Recommendations”, 43.4% for “Funding and declaration and management of interests”, and 43.0% for “Other information”. Conclusions The overall adherence of CPGs on prostate cancer to RIGHT checklist is poor. Following the RIGHT checklist during the development of the guideline could improve the quality of reporting in the future.
Collapse
Affiliation(s)
- Kefeng Liu
- Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.,Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, China
| | - Yanfang Ma
- School of Chinese Medicine of Hong Kong Baptist University, Kowloon Tong, Hong Kong, China
| | - Yongjie Yang
- Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.,Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, China
| | - Jingli Lu
- Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.,Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, China
| | - Jie Zhao
- Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.,Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, China
| | - Shuzhang Du
- Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.,Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, China
| | - Xuepei Zhang
- Urology department, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Chunlei Liu
- Urology department, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Francesco Del Giudice
- Department of Maternal-Infant and Urological Sciences, "Sapienza" University of Rome, Policlinico Umberto I Hospital, Rome, Italy
| | - Masaki Shiota
- Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
| | - Shingo Hatakeyama
- Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
| | - Xiaojian Zhang
- Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.,Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, China
| | - Jian Kang
- Department of Pharmacy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.,Henan Key Laboratory of Precision Clinical Pharmacy, Zhengzhou University, Zhengzhou, China
| |
Collapse
|